Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?;Faut-il doser l'hydroxychloroquine chez les patients lupiques ?

Revue de Medecine Interne

Volumn 27, Issue 9, 2006, Pages 655-657

  Costedoat Chalumeau, N ^a   Amoura, Z ^a   Hulot, J S ^b   Lechat, P ^b   Piette, J C ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hydroxychloroquine; Systemic lupus erythematosus; Therapeutic drug monitoring

Indexed keywords

HYDROXYCHLOROQUINE;

ARTICLE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ETHNOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 33748615429     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.05.002     Document Type: Article

References (21)

1. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324 (1991) 150-154
2. Fessler B.J., Alarcon G.S., McGwin Jr. G., Roseman J., Bastian H.M., Friedman A.W., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52 (2005) 1473-1480
3. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., and Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (1997) 4380-4384
4. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 25 (1996) 191-193
5. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., and Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol. 26 (1999) 325-330
6. Petri M., Lakatta C., Magder L., and Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96 (1994) 254-259
7. Tett S.E., Cutler D.J., and Brown K.F. High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J. Chromatogr. 344 (1985) 241-248
8. Tett S., Day R., and Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br. J. Clin. Pharmacol. 41 (1996) 244-246
9. Tett S.E., Day R.O., and Cutler D.J. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis-a cross sectional study. J. Rheumatol. 20 (1993) 1874-1879
10. Tett S.E., Cutler D.J., Beck C., and Day R.O. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis-a prospective, dose ranging study. J. Rheumatol. 27 (2000) 1656-1660
11. Munster T., Gibbs J.P., Shen D., Baethge B.A., Botstein G.R., Caldwell J., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46 (2002) 1460-1469
12. Osterberg L., and Blaschke T. Drug Therapy: Adherence to Medication. N. Engl. J. Med. 353 (2005) 487-497
13. Petri M., Perez-Gutthann S., Longenecker J.C., and Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am. J. Med. 91 (1991) 345-353
14. Uribe A.G., Alarcon G.S., Sanchez M.L., McGwin Jr. G., Sandoval R., Fessler B.J., et al. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum. 51 (2004) 258-263
15. Mosley-Williams A., Lumley M.A., Gillis M., Leisen J., and Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 47 (2002) 630-638
16. Rojas-Serrano J., and Cardiel M.H. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9 (2000) 601-606
17. Gladman D.D., Koh D.R., Urowitz M.B., and Farewell V.T. Lost-to-follow-up study in systemic lupus erythematosus (SLE). Lupus 9 (2000) 363-367
18. Mirotznik J., Ginzler E., Zagon G., and Baptiste A. Using the health belief model to explain clinic appointment-keeping for the management of a chronic disease condition. J. Community Health 23 (1998) 195-210
19. Cramer J.A., Scheyer R.D., and Mattson R.H. Compliance declines between clinic visits. Arch. Intern. Med. 150 (1990) 1509-1510
20. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Leroux G, Marra D, Aymard G, et al. Intérêt des concentrations très basses d'Hydroxychloroquine comme marqueur objectif de mauvaise adhérence au traitement chez les patients lupiques : facteurs de risque et conséquences. (abstract). Rev. Med. Interne ; (in press).
21. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood Hydroxychloroquine concentrations are a marker and a predictor of exacerbations in treated patients with systemic lupus erythematosus. Arthritis Rheum. ; (in press).